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Background: The introduction of highly-active antiretroviral therapy (HAART) remains a 
major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are com-
monly used as part of triple combinations, given that to antiviral potency, better tolerance and 
convenience has been achieved in recent years.
Objective: To summarize and update evidence-based information about atazanavir (ATV) on 
initial, simplification, and rescue interventions in HIV patients.
Methods: Review of observational and randomized trials reported in medical conferences, 
peer-reviewed journals, and treatment guidelines.
Results: ATV is a second-generation PI, which has shown across studies potent antiviral activity 
and high genetic barrier, both in HAART-naïve patients or after virological failure. Indulgent 
metabolic profile, in terms of insulin glucose and lipid levels, adds value to this drug for the 
long-term management of HIV infection.
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Introduction
The availability of protease inhibitors (PI) has dramatically changed the natural   history 
and treatment of HIV infection. This drug class became available in the mid 90s and 
allowed for the first time, as part of triple combinations, sustained suppression of 
HIV replication followed by immune restoration and prolonged AIDS-free survival. 
Nevertheless, first-generation PI have some disadvantages as compared with other 
drug classes later developed, such as non-nucleoside reverse transcriptase inhibitors 
(NNRTI) or integrase inhibitors (INSTI).1 PI require pharmacokinetic enhancement with 
ritonavir (RTV) to ensure potency and facilitate adherence. Low doses of RTV potently 
inhibit several cytochrome P450 isoenzymes, mainly CYP3A4, which are critical for 
the gastrointestinal and liver clearance of other PI. The net effect is greater plasma 
concentrations of the active PI, which allows twice or once daily dosing and significant 
reductions in pill burden. Poor gastrointestinal tolerance, metabolic   abnormalities, and 
fat redistribution still penalize long-term use of first-generation PI.
Newer PI have been developed to overcome some of the limitations of older PI. 
Among these, ATV , marketed as Reyataz® (Bristol-Myers Squibb) since 2003, should 
be highlighted for its favorable lipid profile, once-daily dosing, low pill burden, and 
high genetic barrier to resistance. Furthermore, ATV may be administered without 
RTV enhancement or, when needed, at low doses not usually related with significant 
adverse effects.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Pharmacology  
and pharmacokinetics of ATV
ATV is an azapeptide inhibitor of the HIV-1 protease, 
with following chemical name:(3S,8S,9S,12S)-3,12-
bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-
9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)
methyl)-2,5,6,10,13-pentazatetradecanedioic acid dimethyl 
ester sulfate (Figure 1). The compound inhibits the virus-
specific   processing of viral Gag and Gag-Pol polyproteins of 
HIV-1 group M, subtypes A, B, C, D, AE, AG, F, G, and J, in 
infected cells thus preventing formation of mature virions.2
In some studies on PI-naïve patients,3,4 the concentration 
that inhibits 50% of viral replication (IC50) in the absence 
of human serum, ranged from 0.6 ng/mL to 5.7 ng/mL. The 
presence of 40% human serum in cell cultures increased 
ATV IC50 by 2.7- to 3.6-fold, as found with other PIs. The 
adjusted IC50 for protein binding was estimated to range 
from 8 to 20 ng/mL against reference viral strains with a 
conventional cycle cell infection and the PhenoSenseTM 
single assay (ViroLogic, Inc, South San Francisco, CA, 
USA), respectively.3
ATV is rapidly absorbed with a Cmax occurring after 
approximately 2.5 h post-dosing, demonstrating non-linear 
pharmacokinetics, a feature that allows once daily posology5,6 
(Table 1). The extent of absorption is highly dependent on 
gastric pH and increases when taken together with food. ATV 
is highly bound to human serum proteins (up to 86%), espe-
cially and in a similar proportion to alpha-1-acid glycoprotein 
and albumin. ATV is a substrate for P-glycoprotein (P-gp), 
an efflux transporter that will act to limit tissue compartment 
distribution. Like other PIs, ATV is extensively metabolized 
by the hepatic cytochrome P450, primarily by the CYP3A4 
and CYP3A5 isoenzymes. ATV metabolites follow biliary 
and urinary excretion for 79% and 13% of the administered 
dose, respectively. Unchanged drug is found in feces and 
urine in proportions of 20% and 7% of the dose administered, 
respectively. Steady-state is achieved after 4 to 8 days of treat-
ment, with a body accumulation of approximately 2.3-fold. 
Finally, ATV enters scarcely the cerebrospinal or semen 
compartments, although improves with RTV boosting.7
Addition of RTV at low doses (100 mg daily) to ATV 
at slightly lower doses (300 mg daily) results in an increase 
of ATV half-life, minimum (Cmin) and maximum concentra-
tions (Cmax), and area under the curve (AUC) as compared 
with ATV 400 mg daily alone. A study involving 214 HIV-
infected patients8 showed a large inter-individual variability 
in ATV disposition, which was associated with factors like 
prior exposure to RTV or nevirapine (NVP), as well as body 
weight.
There are scarce data on the use of ATV in pediatric 
patients and the optimal dosage has not been established. The 
phase I/II PATCG 1020A trial, involving 172 HIV-infected 
children with an age range of 1 to 17 years, studied ATV 
at a dose of 310 mg per m2 of body surface, adjusted over 
24 hours. AUC values showed great variability, which was 
particularly evident between younger and older patients.9
Although liver safety of ATV is proven, pharmacokinetics 
in patients with hepatic impairment remains an important 
issue given major liver metabolism of the drug. Though there 
are few data of ATV use in HIV-infected patients with severe 
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hepatic dysfunction, an increased exposure to ATV should 
be expected. In pharmacokinetic studies carried out in non-
infected adults with moderate to severe hepatic impairment, 
AUC was increased in 42% after a single dose of ATV of 
400 mg, compared with healthy volunteers. On the basis on 
these data, a dose reduction of ATV is advised for patients 
with moderate hepatic dysfunction. In contrast, in a study 
conducted in 58 HCV/HIV-coinfected patients with com-
pensated liver disease, ATV Cmin did not differ significantly 
between patients with and without cirrhosis.10
ATV pharmacokinetics has also been studied in patients 
with renal impairment. Doses of ATV of 400 mg QD have 
been assessed in 20 adults with severe renal impairment, 
including a few in hemodialysis. The mean ATV Cmax was 
9% lower, AUC was 19% higher, and Cmin was 96% higher 
in subjects with severe renal impairment not undergoing 
hemodialysis, than in subjects with normal renal function. 
When ATV was administered either prior to or following 
hemodialysis, the geometric means for Cmax, AUC, and Cmin 
were approximately 25% to 43% lower compared to subjects 
with normal renal function. No dose adjustment is required 
in patients who are not undergoing hemodialysis, and such 
patients should receive the standard dose of 300 mg per day 
of ATV with 100 mg per day of RTV . ATV should not be 
administered in patients with end stage renal disease   managed 
with hemodialysis.2
Some pharmacokinetic studies in pregnant women are 
available. In 12 HIV-infected women receiving boosted 
ATV11 the AUC and Cmin in third trimester of pregnancy 
were approximately 40 and 21% lower, respectively, than in 
non-pregnant HIV-infected women. All individuals reaching 
delivery achieved plasma HIV-RNA , 50 copies/mL and 
all infants tested were HIV-negative and presented normal 
bilirubin levels through day 14. Nevertheless, one newborn 
developed grade 3 hyperbilirubinemia at day 15. In another 
study,12 total bilirubin concentrations in newborns were above 
normal limits at birth and day 3, and three neonates had 
transient jaundice which did not require phototherapy. Data 
obtained in trials assessing other PI in pregnant women13 
  suggest a decrease in plasma exposure during the third tri-
mester. Current guidelines14 consider ATV as an alternative 
regimen to first-line choice with lopinavir (LPV). No evidence 
of human teratogenicity has been communicated to date. 
Furthermore, ATV transplacental passage is low which favors 
fetal safety but may compromise vertical prophylaxis. The 
recommended dosage of ATV during pregnancy is 300 mg 
QD, with 100 mg of RTV . ATV plasma concentrations should 
be monitored throughout the pregnancy period to ensure levels 
greater than 150 ng/mL, although no dose adjustment has yet 
been established.
ATV is a substrate and inhibitor of CYP3A, CYP2C8, 
UGT1A1, and P-gp.15 Therefore, administration of ATV and 
drugs primarily metabolized by these isoenzymes and/or 
substrates of P-gp may cause an increase in plasma concen-
trations of the concomitant drug, potentially enhancing or 
prolonging both their therapeutic and adverse effects. Due 
to afore mentioned inhibitory effect of RTV on CYP3A 
isoenzyme, the magnitude of drug interaction with boosted 
ATV may change. Drugs inducing CYP3A4 and/or P-gp 
metabolism, such as rifampin, may decrease ATV plasma 
concentrations and therefore compromise ATV therapeutic 
effect. Finally, drugs altering the gastric pH may affect 
ATV solubility and consequently its bioavailability. Use of 
proton pump inhibitors along with ATV should be avoided 
(Table 2).
Antiviral efficacy
ATV has shown its efficacy both in treatment-naïve and expe-
rienced patients, with a high genetic barrier, as found in sev-
eral studies (Table 3). The Phase II studies BMS-AI424-007 
and BMS-AI424-008.16,17 The AI424-034 study18 compared 
unboosted ATV (400 mg daily) with EFV in combination with 
zidovudine (AZT) plus lamivudine (3TC) as the nucleoside 
backbone. Probably due to recruitment of a significant num-
ber of patients with high plasma HIV-RNA concentrations 
(42% with $5 log10 copies/mL) and low CD4 counts (median 
of 282 cells/µL), performance after 48 weeks was lower 
than expected, although   comparable between groups (70% 
and 64% of patients attained ,400 HIV-RNA copies/mL 
with ATV and EFV ,   respectively). Both regimens were also 
comparable with respect to the magnitude and rate of CD4 
T-cell gains. EFV was   associated with less favorable outcome 
Table  1  Pharmacokinetic  parameters  at  steady  state  after 
atazanavir (ATV) 400 mg once daily and after atazanavir (ATV) 
300 mg with ritonavir 100 mg once daily with a light meal in HIV-
infected patients2
ATV 400 mg ATV/RTV 300/100 mg
Bioavailability (%) 68 Not available
Protein binding (%) 86 86
Clh (L/h) 25.2 Not available
Clr of parent drug (%) 7 Not available
t1/2, mean ± SD (h) 6.5 ± 2.6 8.6 ± 2.3
Cmax, mean ± SD (ng/mL) 3152 ± 2231 5233 ± 3033
Tmax, median (h) 2 3
Cmin, mean ± SD (ng/mL) 273 ± 298 862 ± 838
AUC, mean ± SD (ng/mLh) 22262 ± 20159 53761 ± 35294HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Main drug interactions with atazanavir (ATV)14
Family Drug Effect on concentration Recommendation
Antiarrhytmics amiodarone, bepridil,  
lidocaine, quinidine
↑ antiarrhytmic Caution is warranted, TDM recommended.
Anticoagulants warfarin ↑ warfarin Monitoring of INR is recommended.
Anticonvulsants carbamazepine,  
phenobarbital phenytoin
expected ↓ ATV Use with caution.
Antidepressants tricyclic antidepressants 
trazodone
↑ tricylcic antidepressants 
↑ trazodone
Use with caution, TDM is recommended. TDM is recommended 
and lower trazodone doses should be used.
Antifungals itraconazole, ketoconazole ↑ itraconazole, ketoconazole  
(ATV 400)
If ATV is used with RTV, itraconazole or ketoconazole doses of 
.200 mg/day should be used with caution.
Antihistamines astemizole, terfenadine no data available ATV/RTV should not be used in combination with drugs that 
are substrates of the CYP3A4 and have narrow therapeutic 
windows, such as terfenadine and astemizole.
Antimicrobial agents clarithromycin ↑ clarithromycin  
↓ 14-OH-clarithromycin  
↑ ATV concentrations
Dose reductions by 50% should be considered. Combination 
with boosted ATV has not yet been studied.
Antimycobacterials rifabutin  
rifampicin
↑ rifabutin  
severe↓ ATV
Reduce rifabutin dose to 150 mg every other day or to 3x/week.  
Contraindicated.
Antiretroviral agents NRTIs:  
didanosine (buffered  
formulation)  
tenofovir
 
↓ ATV, ↓ didanosine  
↓ ATV, ↑ tenofovir
 
Didanosine should be administered 1 h before or 2 h after ATV/
RTV intake.  
Avoid combination of tenofovir with unboosted ATV.
NNRTIs:  
efavirenz  
nevirapine  
etravirine
 
↓ ATV  
expected ↓ ATV  
↑ etravirine, ↓ ATV
 
The recommended dose in treatment-naïve patients is ATV/
RTV 300/100 mg. No recommendation has been established in 
treatment-experienced patients. 
Coadministration is not recommended.  
ATV should be boosted with RTV.
PIs:  
indinavir  
saquinavir  
(soft gelatin capsules)  
tipranavir
 
↑ saquinavir  
expected ↓ ATV
 
Contraindicated due to synergistic effect on hyperbilžrubinemia.  
Appropriate recommendations for this combination have not 
been established. TDM is recommended. 
ATV and tipranavir should not be coadministered.
INSTIs:  
raltegravir
 
↑ raltegravir
 
The clinical relevance of these data is unknown.
Calcium channel  
blockers
diltiazem ↑ diltiazem and  
desacetyl-diltiazem
Caution is warranted. 50% dose reduction of diltiazem should be 
considered.
felodipine, nifedipine,  
nicardipine, verapamil
↑ felodipine, nifedipine,  
nicardipine, verapamil
Caution is warranted and eCG monitoring is recommended. 
Dose titration should be considered.
Corticoesteroids fluticasone ↑ fluticasone Caution is warranted.
ergot derivatives dihydroergotamine, 
ergotamine, ergonovine, 
methylergonovine
↑ ergot derivatives Contraindicated.
Acid suppressive  
therapy
antiacids ↓ ATV ATV should be administered 2 h before or 1 h after intake of 
antacids.
H2 receptor antagonists ↓ ATV H2 receptor antagonist should not exceed a 40 mg dose 
equivalent of famotidine twice daily and ATV should be 
administered with RTV simultaneously, with, and/or at least 10 h 
after the dose of the H2-receptor antagonist.
proton pump inhbitors ↓ ATV ATV/RTV is recommended. Proton-pump inhibitor dose should 
not exceed a 20 mg dose equivalent of omeprazole and must 
be taken approximately 12 h prior to ATV/RTV in antiretroviral-
naïve patients. Proton-pump inhibitors should not be used in 
treatment-experienced patients.
Herbal products worth expected ↓ ATV Contraindicated.
HMG-CoA reductase 
Inhbitors
lovastatin, simvastatin ↑ lovastatin, simvastatin Contraindicated.
(Continued)HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Table 3 Different genotypic resistance scores for atazanavir (boosted or unboosted) in relationship to clinical responses
Source Atazanavir Protease mutations Clinical cut-off
Colonno et al3 Unboosted L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, 
I54L/V, L63P, A71I/V/T, G73A/C/S/T, V82A/F/T/S, I84V, 
L90M, or the presence of I50L alone
,versus $4
ANRS 2004 
www.sante.gouv.fr
Boosted L10F/I/V, K20I/M/R, L24I, L33F/I/V, M36I/L/V, M46I/L, G48V, 
I54L/V, L63P, A71I/V/T, G73A/C/S/T, V82A/F/T/S, I84V, 
L90M, or the presence of I50L alone
,versus $6
ANRS 200539 Boosted L10F/I/V, G16e, L33F/I/V, M46I/L, D60e, I84V, 
I85V, L90M, or the presence of I50L alone
,versus $3
Pellegrin et al40 Boosted L10F/I/V, K20I/M/R, L24I, M46I/L, I54L/V, 
Q58e, L63P, A71I/V/T, G73A/C/S/T, V77I, 
V82A/F/T/S, I84V, L90M, or the presence of I50L alone
,versus $5
Bertoli et al41 Unboosted L10C/I/V, V32I, e34Q, M46I/L, F53L, I54A/M/V, V82A/F/I/T, 
I84V, I15e/G/L/V, H69K/M/N/Q/R/T/Y, I72M/T/V
,versus $4
Bertoli et al41 Boosted G16e, V32I, K20I/M/R/T/V, L33F/I/V, F53L/Y, I64L/M/V, 
A71I/T/V, I85V, I93L/M
,versus $3
Table 2 (Continued)
Family Drug Effect on concentration Recommendation
atorvastatin,  
rosuvastatin
↑ atorvastatin,  
rosuvastatin
Use the lowest possible dose of atorvastatin or rosuvastatin 
with careful monitoring or consider other HMG-CoA reductase 
inhibitor such as pravastatin or fluvastatin.
Immuno-suppressants cyclosporine A, sirolimus, 
tacrolimus
↑ immunosuppressants TDM is recommended.
Neuroleptics pimozide ↑ pimozide Contraindicated.
Oral contraceptives ethinyl estradiol,  
norethindrone
↓↑ oral contraceptives Due to possible alteration of oral contraceptive concentrations, 
alternative/additional contraceptive measures should be used 
when coadministered with ATV or ATV/RTV.
PDe5 inhibitors sildenafil, tadalafil,  
vardenafil
↑ sildenafil, tadalafil,  
vardenafil
Do not exceed 25 mg of sildenafil in 48 h, 10 mg of taldalafil in 
72 h or 2.5 mg of vardenafil in 72 h.
Abbreviations: NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase inhibitor; 
ATV, atazanavir; RTV, ritonavir; TDM, Therapeutic drug monitoring; INR, international normalized ratio; eCG, electrocardiogram.
in lipids (  triglycerides and total LDL and HDL cholesterol) 
as compared with ATV . No significant   variations in glucose 
metabolism were noticed in either group, although patients 
on EFV tended to show slight increases in fasting insulin 
levels.
The AI424-089 study,19 a randomized, multicenter, 
96-week study, compared the efficacy and safety of boosted 
vs unboosted ATV in drug-naïve patients. Although overall 
efficacy results were comparable, rates of response were 
higher and emergence of PI resistance mutations lower in 
subjects on ATV plus RTV than with ATV alone. Concerns 
on a limited potency of unboosted ATV have been noted 
in several antiretroviral treatment guidelines, in which 
ATV alone is only recorded as an alternative option only 
for PI-naïve patients, or in simplification strategies. Use of 
tenofovir (TDF) always require boosted ATV due to lower 
PI exposure, unless ATV plasma levels .150 ng/mL were 
confirmed under ATV alone.
The CASTLE trial,20 an open-label international non-
  inferiority study, randomly assigned 883 treatment-naïve 
patients to receive either boosted ATV or LPV at standard 
doses, in combination with a fixed dose of tenofovir plus 
emtricitabine. After 48 weeks, plasma HIV-RNA ,50   copies/
mL was attained at similar rates in both arms (78% and 
76%, respectively) and CD4 gains were also comparable. 
  Serious adverse events occurred in 12% of patients in the 
ATV group and in 10% of patients in the LPV group. How-
ever, a   better lipid profile was observed in patients receiving 
ATV as compared with LPV . Moreover, gastrointestinal side 
effects were more common in the LPV group, whereas those 
receiving ATV were more likely to experience jaundice. Both 
treatments, however, were in general very well tolerated 
(Figure 2). The 96-weeks21 extension analysis confirmed that 
ATV was superior to LPV in terms of antiviral efficacy. In 
an intention-to-treat (ITT) analysis, 74% of patients in the 
ATV arm achieved HIV-RNA ,50 copies/mL, compared HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
162
Artacho et al
with 68% in the LPV group (P , 0.05). This superior-
ity was also found when stratifying patients according to 
high (.100,000 copies/mL) or low (,100,000 copies/mL) 
baseline HIV-RNA levels. There were no significant differ-
ences among groups when comparing the CD4 cell count 
increase from baseline to 96 weeks (difference of 221 cells/
mL; 95% CI, -43 to 1). Adherence and safety profiles were 
similar in both groups in the extended analysis. Virological 
failures due to resistance were scarce and appeared in simi-
lar proportions in both groups, 6% and 7% in the ATV and 
LPV arms, respectively. The overall incidence of Grades 2–4 
treatment-related adverse events was 30% and 32% in those 
patients on the ATV and LPV regimens, respectively. While 
gastrointestinal side effects were more common in the LPV 
group, hepatobiliary adverse events, namely jaundice and 
hyperbilirubinemia, were more frequent in the ATV group. 
Only 3 patients discontinued ATV therapy due to such events, 
none of them between weeks 48 and 96.
Altogether these studies support the use of once-daily 
boosted ATV as a good first-line treatment option.
Recently, the results of ACTG 5202 trial22 have become 
available. This trial, involving 1,857 HIV treatment-
naïve patients, assessed the efficacy of EFV and boosted 
ATV, combined with either TDF plus FTC or abacavir 
(ABC) plus lamivudine (3TC) with a follow-up period of 
96 weeks. In terms of time to loss of virological response 
(TLOVR), no significant differences were found between 
ATV and EFV regardless nucleoside combination (HR 1.13 
[95% CI,   0.82–1.56] with ABC/3TC and HR 1.01 [95% 
CI, 0.7–1.46] with FTC/TDF). The combination of ABC/3TC 
plus ATV was associated with a longer time to regimen 
modification. Drug resistance rate was significantly lower 
in the ATV group when compared with EFV , regardless of 
nucleoside combination. ATV showed when combined with 
TDF/FTC a greater increase in CD4 cell count. Other trials 
comparing boosted ATV with NVP such as ArTEN23 and 
NEwArT as first-line therapy are ongoing.
RTV-boosted ATV has also been assessed as salvage 
therapy. The AI424-009 study24 was a randomized, multi-
centre, pilot trial that compared the safety and efficacy of 
SQV 1,200 mg QD plus ATV 400 mg or 600 mg QD vs 
RTV boosted SQV 400/400 mg BID. At 48 weeks, the dual 
PI regimens were as effective and well tolerated as RTV plus 
SQV . There were fewer discontinuations caused by adverse 
events in the ATV plus SQV groups (9% and 11%, respec-
tively) than in the RTV plus SQV group (30%). Moreover, 
ATV groups showed significantly lower increase in lipids as 
compared with the SQV plus RTV group (1% vs 10% in total 
NFV
ATV
IDV/r
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LPV/r
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cholesterol, -0.6 vs +23.2% in LDL-cholesterol, and -4.8 
vs +93% in triglyceride levels).
In the AI424-043 study,25 patients who had failed at least 
one PI were rescued with unboosted ATV versus boosted 
LPV. The LPV arm resulted in a significantly greater 
  reduction in plasma HIV-RNA than the ATV arm. Likewise, 
a greater CD4+ T-cell gain was seen with LPV than ATV 
(+169 vs +112 cells/µL). However, whereas LPV increased 
lipid levels and induced insulin resistance, these parameters 
remained stable in the ATV arm.
Finally, the AI424-045 study26 compared boosted ATV 
with boosted LPV in patients who had failed at least two triple 
regimens. Approximately 40% of patients harboured $4 
nucleoside-associated resistance mutations and more than 
one third harboured $4 PI resistance mutations. In the 
intention-to-treat analysis at 96 weeks,27 similar virological 
efficacy was demonstrated for ATV and LPV arms, with 44% 
vs 46% of patients achieving ,400 HIV-RNA copies/mL, 
respectively. Moreover, CD4 gains were comparable (+160 
and +142 cells/µL, respectively). Although response rates 
were similar when fewer than four PI resistance mutations 
were present at baseline, LPV was slightly superior to ATV 
in patients with more than three PI resistance mutations. 
Conversely, the ATV arm benefited from less frequent 
gastrointestinal disturbances and significant reductions in 
total and LDL cholesterol, and triglyceride levels. The main 
drawback was that grade 3–4 hyperbilirubinemia developed 
in 53% of patients on ATV .
ATV has also been studied in several simplification trials. 
In the SLOAT study,28 HIV patients with undetectable plasma 
HIV-RNA for longer than 24 weeks while under boosted 
LPV were randomized to continue on the same therapy or 
switch to boosted (in those on TDF) or unboosted ATV. 
The rate of virological failures at 48 weeks did not differ 
between groups. A significant reduction was seen in median 
total cholesterol and triglycerides in the ATV switch group, 
whereas no significant changes occurred in the control LPV 
arm. Greater reductions in total cholesterol and triglycerides 
were seen in patients switched to unboosted ATV .
The SWAN29 study was a 48-week, open-label, prospec-
tive trial involving HIV patients with virologic suppression 
who were receiving stable PI-based regimens, with or   without 
RTV. Again, patients were randomized 2:1 to boosted or 
unboosted ATV , depending on TDF use, or to continue on 
their prior PI. After 48 weeks, patients switched to ATV 
showed significantly lower total cholesterol, fasting triglycer-
ides, and non-HDL cholesterol than patients in the   comparator 
PI group. For patients with prior exposure to RTV-boosted PI 
regimens, the two treatment groups had comparable rates of 
virologic rebound. In contrast, significantly lower rebound 
rates were recognized for ATV vs comparator PI groups in 
the subset of patients with prior exposure to unboosted PI. 
A limitation of this study was that nearly half of the study 
participants entered the trial receiving obsolete unboosted PI 
modalities, and most of them switched to unboosted ATV , 
which is not the current standard of care.
Finally, boosted ATV has also been assessed as mono-
therapy. The ACTG 5201 study30 was a prospective pilot 
trial with 34 HIV adults with virological suppression 
for $48 weeks receiving their first PI regimen. All partici-
pants switched to boosted ATV at entry and discontinued 
the nucleoside analogue backbone after 6 weeks. Three 
participants (9%) experienced virologic failure at weeks 12, 
14, and 20 after simplification without emergence of any PI 
resistance mutation. Plasma ATV concentrations at failure 
were low or below detection in two out of three subjects. The 
authors concluded that ATV/r maintenance monotherapy 
could be a valuable option in a subset of HIV patients, though 
no predictors of failure were identified.
The ATARITMO study31 tried to determine the   feasibility 
of boosted ATV maintenance monotherapy, along with 
its effects on viral replication, in compartments other than 
plasma; for example, in the cerebrospinal fluid and semen. 
At week 24, 3 of 20 patients had detectable viral load in those 
compartments, despite viral suppression in plasma. As already 
mentioned, the general perception nowadays is that PI mono-
therapy must not be considered as an acceptable optional 
strategy when any other modality of triple antiretroviral 
regimen can be afforded.
Safety and tolerability
ATV is generally well tolerated, as shown by the fact that 
only 5%–10% of patients discontinued the drug due to 
adverse events in the main register trials.1 Indirect bilirubin 
elevation is the most frequent side effect reported, which 
is frequently seen within the first months on ATV therapy 
and tend to slightly decline thereafter due to metabolic com-
pensation mechanisms. This laboratory abnormality only 
achieves clinical relevance (grade 3–4) in up to one third 
of patients across studies. Jaundice is infrequent (,10%) 
and causes ATV discontinuation very rarely (around 1% 
of treated patients). Bilirubin levels seem to be directly 
associated to plasma concentrations of ATV; thus, it is 
more frequent when the drug is boosted with RTV. Of note, 
hyperbilirubinemia is completely reversible after stopping 
ATV. Patients with   Gilbert’s disease or hemolytic anemia HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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caused by thalassemia or ribavirin treatment for hepatitis C 
experience jaundice more frequently when treated with 
AT V. 32 Grade 3–4   elevations in transaminases have been 
observed in 3%–14% of patients receiving ATV. Liver 
enzyme elevations do not correlate with increased serum 
bilirubin, and are more frequently seen in HIV subjects 
with underlying chronic hepatitis B or C. In the   AI424-007 
study,16 in which ATV was given in   combination with 
didanosine and stavudine, grade 3–4 elevations in transami-
nases occurred in 20% of patients with chronic hepatitis B 
and in 40% of patients with chronic hepatitis C, but in ,10% 
of HIV-monoinfected individuals. In studies AI424-00817 
and AI424-034,18 ALT levels .5 times the upper limit of 
normality were seen respectively in 15%, 14% and 17% of 
seropositive patients for hepatitis B or C treated with ATV, 
EFV , and nelfinavir. In study AI424-045,26 20 patients 
treated with ATV/RTV and 18 with LPV/RTV , all seroposi-
tive for hepatitis B and/or C, experienced increases in ALT 
levels .5 times the upper limit of normality in 25% and 
6% of cases,   respectively. Therefore, liver function tests 
should periodically be monitored in patients on ATV with 
underlying chronic liver disease.
Patients on ATV may occasionally complain of gastro-
intestinal disturbances, although symptoms are generally 
mild. In the AI424-00717 study, grade 3–4 nausea/  vomiting, 
abdominal pain, or diarrhea occurred in only 2%–3% of 
patients. Of note, these side effects do not seem to rise when 
ATV is boosted with RTV . Indeed, in the AI424-04528 the 
incidence of grade 2–4 gastrointestinal symptoms was 3% 
in the ATV/RTV arm but was much higher in the LPV/RTV 
arm (11%).
ATV has been shown to prolong the PR interval in 
electro  cardiograms performed on healthy volunteers as 
well as in HIV-infected patients.33 This adversity was not 
originally reported during the clinical development of the 
drug and has only rarely been noticed in the post-marketing 
period.34 Abnormalities in atrioventricular conduction are 
generally asymptomatic, concentration-dependent and 
limited to first-degree atrioventricular block. Anecdotal 
reports of second-degree atrioventricular block and other 
conduction abnormalities have been published. A retro-
spective analysis of patients enrolled in the ATV expanded 
access programme (AI424-900 study35) has shown that 
QRS intervals increased by a median of 5 ms in 75% of 
antiretroviral-experienced patients, using either boosted 
or unboosted ATV . The PR and the QTc intervals did not 
change significantly.   According to pooled data from the 
manufacturer’s prescribing information, the incidence 
of QTc interval prolongation in a total of 1,793 patients 
treated with ATV was comparable to that of patients receiv-
ing other PIs, with none of the patients showing a QTc 
interval .500 ms. An additive effect of ATV and drugs 
that prolong the PR interval (eg, beta-blockers, verapamil, 
digoxin) and the QT interval cannot be excluded. Hence, 
when possible these combinations should be avoided. 
Though very rare, these findings could support periodically 
performing electrocardiogram monitoring in patients treated 
with ATV , particularly when boosted with RTV .
Unlike other PIs, ATV seems to have a favorable 
metabolic profile, namely regarding lipid abnormalities and 
insulin resistance.36
Nephrolithiasis has also been rarely related with ATV 
exposure,37 cause by precipitation of the active principle in 
the urinary tract. In one retrospective study the prevalence 
of ATV-associated urolithiasis was 0.97%.38 Patients with 
low water intake, high urinary pH, and prior history of 
urinary stones are at higher risk for ATV-associated urine 
crystallization.
Conclusions
ATV is an antiretroviral drug that provides a well proven antiviral 
efficacy, high genetic barrier, low daily pill burden, as well as 
a more friendly metabolic profile than previous PI. Although 
ATV is one of the most recently developed PI, there is already 
strong evidence available for allowing the inclusion of ATV 
in most guidelines as a preferred regimen. DHHS guidelines 
include once-daily ATV/r as one of the preferred regimens in 
combination with emtricitabine (FTC) and tenofovir (TDF) 
as nucleoside analog backbone. ATV/r can also be combined 
with abacavir (ABC) or zidovudine (AZT) plus lamivudine 
(3TC), in what has been considered an alternative regimen. 
Unboosted ATV can be used in combination with ABC or AZT 
plus 3TC in cases when RTV boosting is not posssible. The 
2009 European AIDS Clinical Society Guidelines consider 
ATV/r as a recommended regimen when combined with either 
FTC plus TDF or ABC plus 3TC.
Available evidence supports the widespread use of ATV 
as base for HAART regimens both in treatment-naïve or 
pretreated patients. Though having been available since 
2003, there is enough data from lengthy trials confirming 
ATV as an efficacious antiretroviral, with a high genetic 
barrier and a rather friendly metabolic profile. Its favor-
able safety profile, low daily pill burden and the once-daily 
administration favors a high adherence to ATV-containing 
HAART regimens, making ATV a very interesting drug for 
HIV treatment.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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